Vanguard Capital Management
CHRS icon

Vanguard Capital Management’s Coherus Oncology CHRS Stock Holding History

Vanguard Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.33M Buy
5,949,490
+496,728
+9% +$811K ﹤0.01% 2927
2026
Q1 		$9.22M Buy
+5,452,762
New +$9.68M ﹤0.01% 2773

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Capital Management's CHRS Position: Q2 2026 in Review

Vanguard Capital Management increased its Coherus Oncology (CHRS) stake by 9.1% in Q2 2026, buying an estimated $811K and bringing the position to 5,949,490 shares worth $8.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

Vanguard Capital Management first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.22M in Q1 2026. 145 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Vanguard Capital Management held 5,949,490 shares of Coherus Oncology worth $8.33M as of Q2 2026.
  • Vanguard Capital Management bought 496,728 Coherus Oncology shares in Q2 2026, an estimated $811K.
  • Coherus Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2927 holding.
  • Vanguard Capital Management first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Coherus Oncology position peaked at $9.22M in Q1 2026.
  • 145 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.